Caveolin induces cardioprotection through epigenetic regulation

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 4, 2012, Pages 888-895

  Das, Manika ^a   Das, Somak ^a   Lekli, Istvan ^a   Das, Dipak K ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Cardioprotection; Caveolin; Epigenetics; Hat; Hdac; Histone

Indexed keywords

CARDIOTONIC AGENT; CAVEOLIN 1; HISTONE DEACETYLASE;

ACETYLATION; ANIMAL; APOPTOSIS; ARTICLE; GENETIC EPIGENESIS; GENETICS; IN VITRO STUDY; METABOLISM; METHYLATION; MOUSE; MOUSE MUTANT; PHYSIOLOGY;

ACETYLATION; ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; CAVEOLIN 1; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; METHYLATION; MICE; MICE, KNOCKOUT;

EID: 84867880722     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01372.x     Document Type: Article

References (29)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update. Circulation. 2007; 115: E69-171.
2. Lee TM, Lin MS, Chang NC. Inhibition of histone deacetylase on ventricular remodeling in infracted rats. Am J Physiol Circ Physiol. 2007; 293: H968-77.
3. Zhao TC, Cheng G, Zhang LX, et al. Inhibition of histone deacetylase triggers pharmacological preconditioning effects against myocardial ischemic injury. Cardiovasc Res. 2007; 76: 473-81.
4. Jenuwein T, Allis CD. Translating the histone code. Science. 2001; 293: 1074-80.
5. Zhang, CL, McKinsey TA, Chang S, et al. Class II histone deacetylase act as signalresponsive repressor of cardiac hypertrophy. Cell. 2002; 110: 479-88.
6. Peterson CL, Laniel MA. Histone and histone modifications. Curr Biol. 2004; 14: R546-51.
7. Rice JC, Briggs SD, Ueberheide B. Histone methyltransferase direct different degree of methylation to define distinct chromatin domains. Mol Cell. 2003; 12: 1591-8.
8. Cohen AW, Park DS, Woodman SE, et al. Caveolin-1 null mice develop cardiachypertrophy with hyper activation of p42/44 kinase in cardiac fibroblasts. Am J Physiol Cell Physiol. 2004; 284; C457-74.
9. Woodman SE, Park DS, Cohen AW, et al. Caveolin-3 knockout mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem. 2002; 277: 38988-97.
10. Park DS, Woodman SE, Schubert W, et al. Caveolin 1/3 double knockout mice are viable but lack both muscle and nonmuscle caveolae and develop a severe cardiomyopathic phenotype. Am J Pathol. 2002; 160: 2207-17.
11. Das M, Cui J, Das DK. Generation of survival signal by differential interaction of p38MAPKα and p38MAPKβ with caveolin-1 and caveolin-3 in the adapted heart. J Mol Cell Cardiol. 2007; 42: 206-13.
12. Gurusamy N, Lekli I, Ahsan MK, et al. Downregulation of cardiac lineage protein-1 confers cardioprotection through the upregulation of redox effectors. FEBS Lett. 2010; 584: 187-93.
13. Yang SR, Valvo S, Yao H, et al. IKK alpha causes chromatin modification on proinflammatory genes by cigarette smoke in mouse lung. Am J Respir Cell Mol Biol. 2008; 38: 689-98.
14. Chen H, Yan Y, Davidson TL, et al. hypoxic stress induces dimethylated histine H3 lysine 9 through histine methyltransferase G9a in Mammalian cells. Cancer Res. 2006; 66: 9009-16.
15. Cheung P, Allis CD, Sassone-Corsi P. Signaling to chromatin through histone modifications. Cell. 2000; 103: 263-7.
16. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000; 404: 41-5.
17. Turner BM. Histone acetylation and an epigenetic code. BioEssaya 2000; 22: 836-45.
18. Ren M, Leng Y, Jeong K, et al. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential role of histone deacetylase inhibition and heat shock protein induction. J Neurochem. 2004; 89: 1358-67.
19. Antos CL, McKinsey TA, Dreitz M, et al. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem. 2003; 278: 28930-7.
20. Kee HJ, Sohn IS, Nam KI, et al. Inhibition of histone acetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding, Circulation. 2006; 113: 51-9.
21. Greer EL, Brunet A. FOXO transcription factors in ageing and cancer. Acta Physiol. 2008; 192: 19-28.
22. Kops GJ, Dansen TB, Polderman PE, et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature. 2002; 419: 316-21.
23. Yang Y, Hou H, Haller EM, et al. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J. 2005; 24: 1021-32.
24. Vogt PK, Jiang H, Aoki M. Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle. 2005; 4: 908-13.
25. Lal G, Bromberg JS. Epigenetic mechanism of regulation of Foxp3 expression. Blood. 2009; 114: 3727-35.
26. Lavelle D, Chen YH, Hankewycls M, et al. Histone acelates induce apoptosis of p21 and myeloma cell lines of IL-6 receptor expression. Am J Hemotol. 2001; 68: 170-8.
27. McGee SL, van Denderen BJW, Howlett KF, et al. AMP-activated protein kinase regulates GLUT 4 transcription by phosphorylating histone deacylase 5. Diabetes. 2008; 57: 860-7.
28. Michael Haberland M, Rusty L, Montgomery RL, et al. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nature Rev Genetics. 2009; 10: 32-42.
29. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumour suppression. Oncogene. 2005; 24: 7410-25.